Combination Tx of SGLT2 Inhibitor and Exenatide May Improve Renal, Mortality Outcomes
Combination treatment with a SGLT2 inhibitor and exenatide may protect renal function and reduce all-cause mortality risk in patients with type 2 diabetes.
Type 2 Diabetes
Empagliflozin May Reduce Liver Fat Content in Patients With Type 2 Diabetes
Treatment with empagliflozin may reduce liver fat content and increase serum adiponectin in patients with well-controlled type 2 diabetes.
Vitamin D Does Not Delay T2D in High-Risk Patients
Supplementation with vitamin D does not delay onset of type 2 diabetes in high-risk patients.
Chiglitazar Safe, Effective in Phase 3 Diabetes Trial
Investigators examined the safety and efficacy of chiglitazar in patients with type 2 diabetes that is inadequately controlled with lifestyle interventions.
